Obesity medication coverage has historically faced barriers, though recent precedents with Wegovy and Zepbound approvals suggest improving coverage landscape
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test examines variants in metabolic and temperature-regulating pathwaysincluding the FTO gene (rs9939609), which influences energy expenditure and body composition changes
You might notice you sleep better, wake up feeling more refreshed, or have more stamina throughout the day
Adults with a BMI of 27 or higher (overweight): You may be eligible if you also have at least one weight-related health condition, such as: Type 2 diabetes High blood pressure High cholesterol These medications are recommended for individuals who have tried losing weight through lifestyle changes but have not achieved significant or sustainable results
Patients who develop new symptoms potentially attributable to low testosterone during semaglutide therapy should be evaluated clinically and biochemically
Click for more Ozempic Updates June 2, 2026 Court Holds Science Day in GLP-1 Vision Loss Litigation Judge Marston held a Science Day in the NAION MDL to hear presentations on the medical and scientific evidence surrounding GLP-1 drugs and sudden vision loss
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
